TapImmune (TPIV): U.S. Department of Defense Fully Funds Phase II Breast Cancer Study

From MicrocapResearch.com – Researching The Best Microcap Stocks
May 9, 2017 - 8:15am
TapImmune (TPIV) is advancing two Phase II studies that are funded by ~$17 million in non-dilutive grants from the U.S. Department of Defense. In total, the company has 4 different Phase II studies underway and is planning to submit an Investigational New Drug (IND) Application with the FDA for another breast cancer vaccine this year. Due to the unmet… Continue reading → The post TapImmune (TPIV): U.S. Department of Defense Fully Funds Phase II Breast Cancer Study appeared first on MicrocapResearch.com - Researching The Best Microcap Stocks.


Continue reading this article »